Clinical and radiological outcomes of directed treatment transitions from Gilenya <sup>®</sup> to generic fingolimod
Measures of disease stability appear less optimal with generic fingolimod based on serological, clinical, and radiological measures.
Authors
- Benjamin Greenberg (ORCID: https://orcid.org/0000-0002-2091-8201)
- Paula Hardeman
- Darin T. Okuda (ORCID: https://orcid.org/0000-0002-6499-1523)
- Katy W. Burgess
- Peter V. Sguigna (ORCID: https://orcid.org/0000-0003-1825-575X)
- Lauren Tardo (ORCID: https://orcid.org/0000-0003-0214-633X)
- Crystal Wright
- Morgan McCreary (ORCID: https://orcid.org/0000-0002-8378-460X)
- Kevin Shan (ORCID: https://orcid.org/0000-0003-1829-0387)
- Mahi A. Patel (ORCID: https://orcid.org/0009-0002-8245-2336)
- Shanan B. Munoz
- Tom G. Punnen
- Lindsay A Horton
- Olaf Stüve
Institutions
- Kansas City University (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2026-01-03
- DOI
- https://doi.org/10.1177/13524585251401404
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00